GRANTS / FUNDING
Funding for Phase
1 & 2
WP1732 has benefitted from over $1 million in grants and subsequently sponsored research at MD Anderson Cancer Center and is expected to receive over $3 million in the next 24 months for Phase I and II clinical trials.
IND-enabling toxicology work is progressing and expectations are an IND will be submitted to the FDA in 2019.
DRUG DISCOVERY & DEVELOPMENT
leading cancer research center in the world, drug discovery.
Moleculin Biotech, Inc.
ALS’ development partner has begun planning and performing the preclinical work necessary to submit an IND for WP1732 and entered into an agreement with The University of Iowa Pharmaceuticals for the development of a formulation for WP1732.
Additional indications could include a wide range of tumors, including lung, stomach and head & neck cancers, as well as use in combination with checkpoint inhibitors and cytotoxic agents. Hematological malignancies are potential additional indications for intravenously (IV) administered WP1732.